This is significant as antibodies that target the RBD have the potential to be neutralising and thus prevent future infection by blocking the virus from entering the cell. The Beckman Coulter Access SARS-CoV-2 IgG assay detects immunoglobulin G (IgG) and targets antibodies that recognise the receptor-binding domain (RBD) of the spike protein which SARS-CoV-2 uses to bind to a human cell receptor.
“Henry Ford found when running the Beckman Coulter SARS-CoV-2 assay on 204 PCR-confirmed COVID-19 patient samples, a test sensitivity of 100% at 14 days post-PCR and testing of 80 patient samples from the pre-COVID era yielded a specificity of 100%.” “We selected the Beckman Coulter Access SARS-CoV-2 IgG antibody assay to be the backbone of Henry Ford’s COVID-19 serology testing program because of its outstanding performance in our rigorous independent evaluation,” said Dr Bernard C Cook, Division Head of Chemistry-Pathology, Henry Ford Health System. Henry Ford Health System was one of the first health systems to receive Beckman Coulter’s test and independently validate its performance. Beckman Coulter has more than 16,000 immunoassay analysers worldwide and has ramped its manufacturing to deliver more than 30 million tests a month. and has begun shipping to customers globally. The company has already shipped tests to more than 400 hospitals, clinics and diagnostics laboratories in the U.S.
Beckman Coulter has announced that its Access SARS-CoV-2 IgG assay is now available in markets accepting the CE Mark.
0 kommentar(er)
